THERAPY DOSSIER · th-06045ffaec90

Tamsulosin

Drug · Adrenergic receptor alpha-1 antagonist

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Adrenergic receptor alpha-1 antagonist
Target: CHEMBL2094251
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: 1997
Development stage: Not recorded
ChEMBL record: CHEMBL836 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Flomax; Harnal; YM-617; LY-253351; Tamsulosin hydrochloride; HGP-0412; HIP-1402
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00771394 ↗PHASE4completed

Solifenacin Succinate as Add-on Therapy for OAB Symptoms in Men Treated for BPH With Tamsulosin Hydrochloride

Benign Prostatic Hyperplasia · Overactive Bladder

Enrolment: 638 · Results not recorded

NCT01880619 ↗PHASE4completed

Tamsulosin vs Solifenacin in Treatment of Ureteral Stent Related Symptoms

Ureteral Stent Symptoms

Enrolment: 131 · Results not recorded

NCT04491526 ↗PHASE4terminated

Prophylactic Tamsulosin in Prevention of Postoperative Urinary Retention After Endoscopic TEP Inguinal Hernia Repair

Urinary Retention · Inguinal Hernia

Enrolment: 312 · Results not recorded

NCT02443844 ↗PHASE4unknown

Medical (Tamsulosin) vs Surgical Treatment of BPH in Low Grade Non Muscle Invasive Bladder Cancer

Bladder Cancer

Enrolment: 40 · Results not recorded

NCT00884104 ↗PHASE4completed

Predictive Factors for Solifenacin Add-on in Men With Residual OAB Symptoms After Tamsulosin Monotherapy

Overactive Bladder

Enrolment: 307 · Results not recorded

NCT05570084 ↗PHASE3unknown

Silodosin Versus Tamsulosin for Medical Expulsive Treatment of Ureteral Stones 5-10 mm

Stone, Urinary

Enrolment: 80 · Results not recorded

NCT00796614 ↗PHASE2/PHASE3completed

Phase IIb/III Dose Ranging Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder

Bladder, Neurogenic

Enrolment: 231 · Results not recorded

NCT02529800 ↗PHASE1completed

Single Dose Three-way Crossover PK Trial of HIP1402 (tamsulosin) in Healthy Male Volunteers

Healthy

Enrolment: 24 · Results not recorded

NCT00264017 ↗NAcompleted

Palladium-103 Seed Implant With Uroxatral vs Flomax (tamsulosin) - 3 Month Retrospective Efficacy Analysis

Prostate Cancer

Enrolment: 60 · Results not recorded

NCT00954889 ↗NAunknown

Clinical Effect and Safety of Tamsulosin 0.4 mg in LUTS/BPH Refractory to Tamsulosin 0.2 mg

Benign Prostatic Hyperplasia

Enrolment: 220 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25229021 ↗2014Mixed findings

Effects of bladder function by early tamsulosin treatment in a spinal cord injury rat model.

RatSpinal cord injuryComplete transectionSprague DawleyFemalen = 45 rats total: control n=12, spinal cord injury n=12, spina…Intraperitoneal0.1 mg/kgEarly treatment beginning after spinal cord transection, continued for 7 days

Model: Complete spinal cord transection at T10 vertebral level

Tamsulosin significantly reduced acetylcholine-induced detrusor contractility relative to untreated spinal cord injury, including after 4-DAMP pretreatment, and normalised protein expression with higher pERK1/2 and lower rho-kinase. However, awake cystometry showed no significant difference between…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…